Glenmark Pharmaceuticals’ triamcinolone acetonide cream 0.1% has been granted FDA approval. The product is the generic version of Delcor Asset Corporation’s Kenalog cream, which is no longer available in the US market.

Triamcinolone acetonide cream is typically prescribed to treat itching, redness, dryness, and scaling due to a variety of skin conditions. It’s also used to relieve mouth sores, depending on the individual. In addition to cream, triamcinolone acetonide is available in liquid, lotion, ointment, nasal spray, and aerosol formulations.

The most common adverse effects associated with the use of triamcinolone acetonide cream are acne, drying or cracking of skin, itching, burning, and change in skin color. Others that may occur include severe skin rash, difficulty breathing or swallowing, wheezing, and skin infection (redness, swelling, oozing of pus). Any severe adverse effects should be reported to a health care professional and may also be submitted to the FDA’s MedWatch Adverse Event Reporting program.

Patients should keep track of other prescription and nonprescription medications while using triamcinolone acetonide cream.

For the 12 months ending in June 2016, Kenalog 0.1% had annual sales of $43 million, according to IMS Health.